Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia

Key facts

Sponsor

Washington University School of Medicine

Principal Investigator

Shalini Shenoy, MD

Washington University School of Medicine

Intervention

Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan(drug)

Enrollment

21 target

Eligibility

1-16 years · All sexes

Timeline

2010 – 2014

Study locations (18)

• Regents of University of California- UCLA, Los Angeles, California, United States
• Children's Hospital and Research Center at Oakland, Oakland, California, United States
• Children's National Medical Center, Washington D.C., District of Columbia, United States
• University of Miami, Miami, Florida, United States
• All Children's Research Institute, Inc., St. Petersburg, Florida, United States
• Emory University, Atlanta, Georgia, United States
• Children's Memorial Hospital, Chicago, Illinois, United States
• Dana Farber Cancer Institute, Boston, Massachusetts, United States
• University of Michigan, Ann Arbor, Michigan, United States
• Washington University, St Louis, Missouri, United States
• The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
• Duke University, Durham, North Carolina, United States
• The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States
• Oregon Health and Science University, Portland, Oregon, United States
• The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
• +3 more locations on ClinicalTrials.gov

Collaborators

Carelon Research · Pediatric Blood and Marrow Transplant Consortium

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Thalassemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07338344
  Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients
  Rongrong Liu
• RECRUITINGNANCT07112703
  Effect of Incentive Respiratory Training on Pulmonary Functions and Functional Capacity in Children With B-thalassemia Major
  Rawan Mohammed Khairy Mostafa Elsawy
• RECRUITINGPHASE3NCT06609226
  A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
  Novo Nordisk A/S
• RECRUITINGNANCT06931912
  Growth Evaluation, Health Promotion, and Clinical Management in Children and Adolescents With Thalassemia
  Institute of Hematology & Blood Diseases Hospital, China
• RECRUITINGPHASE2NCT06657391
  Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia
  Rongrong Liu
• ENROLLING BY INVITATIONNCT07003269
  Observational Study: Hetrombopag for Platelet Recovery in Haploidentical HSCT
  Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
• ACTIVE NOT RECRUITINGNCT06596642
  A Real-World Study of β-Thalassemia Major Treatment With Luspatercept in Taiwan
  Bristol-Myers Squibb
• RECRUITINGPHASE1NCT06655662
  Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.
  Shenzhen Hemogen

See all trials for Thalassemia →